Letrozole

Letrozole (brand name Femara) is best known as a breast cancer treatment for postmenopausal women, lowering estrogen by blocking the aromatase enzyme; it's a potent aromatase inhibitor. It's a small-molecule oral drug, not a peptide. It's FDA-approved for that breast-cancer use; all use in men is off-label.

Letrozole is used mainly to treat breast cancer in postmenopausal women, and studied off-label in men to lower estrogen and raise testosterone. It's FDA-approved for the breast-cancer use. In the large BIG 1-98 trial in postmenopausal women with breast cancer, letrozole reduced recurrence compared with tamoxifen. In men, a 2013 placebo-controlled trial in obese men with low testosterone found it reliably suppressed estradiol and raised testosterone but produced no significant benefit on the predefined body-composition or psychological measures, so the hormone effect is robust while the clinical benefit in men is uncertain.

FDA-approved (Femara, Novartis; NDA 020726, originally approved 1997 for advanced postmenopausal breast cancer; subsequent approvals for adjuvant and extended-adjuvant treatment of early-stage hormone-receptor-positive breast cancer in postmenopausal women). Generic letrozole has been widely available since 2011 (US patent expiry). FDA-approved indications are exclusively in postmenopausal women with breast cancer; all use in men is off-label, paralleling the Anastrozole regulatory pattern. Listed in the WADA 2026 Prohibited List under S4.1 (Aromatase Inhibitors) as a Specified Substance — explicitly named alongside anastrozole, exemestane, and aminoglutethimide.

Letrozole is a prescription-only medication, FDA-approved only for breast cancer in postmenopausal women; it is banned in WADA-tested sport, and its higher potency makes over-suppression of estrogen (with effects on mood, libido, joints, and bone) a particular concern. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Letrozole is FDA-approved for postmenopausal breast cancer indications, but all use in men is off-label. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions, particularly for off-label men's-health use which lacks FDA-approval-grade clinical guidance.

⚠️ Pill-splitting accuracy at sub-1-mg doses. Letrozole's FDA-approved dose for breast cancer is once daily — a single full Femara tablet. Off-label men's-health protocols typically use much lower doses (often per dose, several times per week), requiring pill-splitting of the tablet into halves, quarters, or eighths. Pill-splitting accuracy degrades substantially below the half-tablet level — a quartered or eighthed tablet will rarely produce equal doses. Researchers using letrozole at sub- doses should use a tablet splitter and accept that day-to-day dose variability will be greater than the nominal dose suggests. Compounded letrozole (available from 503A pharmacies) at custom strengths (e.g. or capsules) is a more precise alternative.

⚠️ Off-label men's-health use is supported by mechanism but not by RCT-grade efficacy data for somatic or psychological endpoints. A 2013 randomized placebo-controlled trial of low-dose letrozole in obese men with hypogonadotropic hypotestosteronemia (Loves et al.) confirmed letrozole effectively suppresses estradiol and raises testosterone, but found no significant somatic or psychological benefits at the predefined endpoints (body composition, exercise capacity, glucose/lipid/bone metabolism, psychological function).[³] This is an important nuance for researchers extrapolating breast cancer trial data into men's-health use: the biochemical effect is robust and reproducible, but the clinical translation to symptom or body-composition benefit in men is not established by the available RCT evidence base.

⚠️ Letrozole achieves near-complete aromatase inhibition at its standard dose. Letrozole produces approximately >99% aromatase inhibition at the standard dose; anastrozole produces ~97%. This translates to greater estradiol suppression — which is the goal in postmenopausal breast cancer adjuvant therapy, but is the load-bearing safety concern in men's-health off-label use, where over-suppression of estradiol produces clinically meaningful harm (mood disturbance, low-libido, joint pain, accelerated bone loss). Researchers switching from anastrozole to letrozole or considering letrozole as a first-line off-label AI should account for the higher per-mg potency in their starting dose selection.

⚠️ WADA-prohibited at all times under S4.1. Letrozole is listed by name on the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors).[⁵] Aromatase inhibitors are Specified Substances under WADA — meaning the standard adverse-finding penalty path applies (typically 2-year ban for a first violation, reducible upon establishment of no fault or no significant fault). Researchers competing in WADA-tested sport should not use letrozole.

Letrozole (CGS 20267, brand name Femara) is a third-generation nonsteroidal aromatase inhibitor developed by Novartis in the 1990s. The compound is a benzyl-triazole derivative that selectively and reversibly binds the heme iron of the aromatase (CYP19A1) enzyme, inhibiting the conversion of androstenedione to estrone and testosterone to estradiol. Letrozole shares its mechanism of action with anastrozole (Arimidex) — both are nonsteroidal, reversible, third-generation AIs — but differs structurally in being a triazole (vs anastrozole's pyrrole) and in its per-milligram aromatase-inhibition potency (see the mechanism comparison below). The compound was FDA-approved (NDA 020726) in 1997 for advanced postmenopausal breast cancer; subsequent approvals expanded the indication to adjuvant and extended-adjuvant treatment of early-stage hormone-receptor-positive breast cancer in postmenopausal women.

FDA-approved indication and the BIG 1-98 trial. Letrozole's pivotal Phase 3 trial in adjuvant breast cancer was the Breast International Group (BIG) 1-98 study, a randomized, double-blind, multicenter trial that compared letrozole, tamoxifen, and the two sequential combinations as 5-year adjuvant therapy in postmenopausal women with hormone-receptor-positive early breast cancer.[¹] The 2005 NEJM publication of the primary results (Thürlimann et al., 14-author byline, n=8,010 across the four treatment arms) reported that 5 years of letrozole significantly reduced the risk of recurrence compared with 5 years of tamoxifen (hazard ratio 0.81 for any disease-free-survival event; HR 0.73 for distant recurrence), with 5-year disease-free survival of 84.0% (letrozole) vs 81.4% (tamoxifen). The safety profile differed by treatment: tamoxifen produced more thromboembolism, endometrial cancer, and vaginal bleeding; letrozole produced more skeletal events and hypercholesterolemia. BIG 1-98 was the foundational trial that established AIs (including letrozole and anastrozole) as first-line adjuvant endocrine therapy for postmenopausal hormone-receptor-positive breast cancer, displacing tamoxifen monotherapy as the prior standard of care.

Mechanism — comparison to anastrozole and exemestane. All three FDA-approved third-generation AIs act on the aromatase enzyme but differ structurally and pharmacologically. Letrozole (triazole, nonsteroidal, reversible) achieves >99% aromatase inhibition. Anastrozole (pyrrole, nonsteroidal, reversible) achieves ~97% aromatase inhibition. Exemestane (steroidal, irreversible — see [exemestane.md](./exemestane.md)) is mechanistically distinct in being a substrate-mimetic that covalently binds and permanently inactivates the enzyme (overcome only by new enzyme synthesis). The two nonsteroidal AIs (letrozole and anastrozole) share a common mechanism profile and cross-resistance pattern; exemestane's distinct mechanism makes it active in some letrozole/anastrozole-resistant settings. The clinical efficacy difference between letrozole and anastrozole at standard doses has been compared in multiple head-to-head studies and meta-analyses; the FACE trial (Femara vs Arimidex Clinical Evaluation, 2013) found similar disease-free survival outcomes at 5 years.[¹]

Off-label men's-health use — testosterone-supportive protocols. As with anastrozole (see [anastrozole.md](./anastrozole.md)), letrozole's mechanism of suppressing estradiol synthesis from testosterone substrate makes it relevant to men's-health protocols where elevated estradiol or aromatization is a concern — most commonly: (1) men on testosterone replacement therapy who develop estradiol-related side effects (gynecomastia, water retention, mood disturbance) requiring estrogen-management; (2) men with obesity-related hypogonadotropic hypotestosteronemia, where elevated peripheral aromatase activity contributes to low total testosterone; (3) men using anabolic-androgenic steroid protocols (research-community context) for estrogen-management on cycle. Off-label use in men is supported by mechanism but the clinical translation to symptom or body-composition benefit is not established by the available RCT evidence base. The 2013 Loves et al. trial of low-dose letrozole in 42 obese hypogonadal men (titrated to achieve serum testosterone of 20 nmol/L) confirmed the biochemical effect (estradiol decreased ~50%, LH increased ~3-fold, total testosterone increased ~2.5-fold) but found no significant effects on the predefined somatic or psychological endpoints despite the marked testosterone rise.[³] This is the strongest RCT-grade evidence available for letrozole in obese hypogonadal men, and the result is best summarized as "biochemical effect robust, clinical translation uncertain."

Regulatory status. Letrozole was FDA-approved (NDA 020726) on July 25, 1997, for advanced postmenopausal breast cancer. The adjuvant indication followed in 2005, and the extended-adjuvant indication (after 5 years of tamoxifen) followed thereafter. Generic letrozole became widely available in 2011 after US patent expiry. FDA-approved use is exclusively in postmenopausal women; all use in men, premenopausal women (other than for ovulation induction in fertility contexts, where letrozole is also used off-label), and adolescents is off-label. Letrozole is listed by name in the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors) as a Specified Substance[⁵] — researchers competing in WADA-tested sport should not use letrozole.

Common research interests. Letrozole's research-community use spans: (a) the clinically validated postmenopausal breast cancer indication (per FDA-approved use); (b) off-label men's-health use for estrogen-management on TRT or AAS protocols; (c) off-label fertility use for ovulation induction in PCOS (the Birmingham/Legro trials established letrozole as superior to clomiphene for ovulation induction in PCOS — but this use is FDA-off-label and is covered indirectly elsewhere in the library via the Clomiphene/Enclomiphene entry's regulatory framing); (d) niche pediatric endocrinology use for short stature (off-label, controversial). The Vialwise library's framing is focused on (a) and (b), with brief acknowledgment of (c) where relevant; (d) is outside the library's scope.

Commonly reported

• Hot flashes (~33% of patients)
• Arthralgia and joint stiffness (~20–30%, often dose-limiting)
• Fatigue (~13%)
• Headache (~8%)
• Nausea (~8%)
• Hypercholesterolemia (~6–10% — meaningful for cardiovascular risk over multi-year courses)
• Skeletal events (osteopenia, fractures — increased relative to tamoxifen at 5 years per BIG 1-98)
• Vaginal dryness or atrophy (in postmenopausal women)
• Mood changes, irritability, low libido (in men using letrozole off-label, attributable to estradiol over-suppression)

Serious

• Severe joint pain or new arthralgia preventing daily activity
• Symptoms of bone loss or non-traumatic fracture (back pain, height loss)
• Severe mood disturbance, depression, or suicidal ideation
• Cardiovascular events or new chest pain
• Significant elevation in cholesterol or lipid panel (typically asymptomatic — labs detect)
• Severe vaginal bleeding (in women)
• Severe persistent fatigue or weakness

Premenopausal women — FDA labeling specifies postmenopausal use; premenopausal women have intact ovarian estradiol synthesis that is not adequately suppressed by AI alone (and AI use without ovarian suppression can paradoxically increase ovarian estradiol via reduced negative feedback).

Pregnancy — Pregnancy Category X. Contraindicated; teratogenic in animal models. Women of reproductive potential should use effective contraception during use and for 3 weeks after the last dose.

Lactation — contraindicated.

Severe hepatic impairment — letrozole is hepatically metabolized; dose reduction is recommended for cirrhotic patients.

Severe osteoporosis or known osteopenia — caution; AIs accelerate bone loss. Baseline DEXA and ongoing monitoring are recommended.

Active cardiovascular disease — caution; AIs increase cholesterol and may modestly increase cardiovascular risk over multi-year courses.

Concurrent use of estrogen-containing therapies (oral contraceptives, hormone replacement therapy) — pharmacologically counterproductive.

Regulatory note (US): Letrozole is FDA-approved for postmenopausal breast cancer indications. All use in men, premenopausal women (except for off-label fertility use), and adolescents is off-label.

Regulatory note (WADA): Letrozole is listed by name in the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors) as a Specified Substance.[⁵] Researchers competing in WADA-tested sport should not use letrozole.

Aromatase inhibitor

A drug that blocks the aromatase enzyme, which converts androgens into estrogen, thereby lowering estrogen levels.

Off-label use

Use of an approved drug for a condition or population not listed on its FDA-approved label.

Estradiol

The main form of estrogen; relevant in men because some testosterone is converted to estradiol.

Testosterone replacement therapy (TRT)

Medically supervised use of testosterone to treat men with diagnosed low testosterone.

1. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353(26):2747-57.(PMID 16382061 · NCT00004205)
2. US Food and Drug Administration. Femara (letrozole) Prescribing Information. Manufacturer: Novartis. NDA 020726, originally approved July 25, 1997 (advanced breast cancer); subsequent supplemental approvals for adjuvant and extended-adjuvant indications. FDA Orange Book and
3. Loves S, de Jong J, van Sorge A, Telting D, Tack CJ, Hermus A, Westerterp K, de Boer H. (2013). Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. European Journal of Endocrinology, 169(5):705-14.(PMID 23949882)
4. Smith IE, Dowsett M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24):2431-42.(PMID 12802030)
5. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (linked from the WADA landing page at wada-ama.org/en/prohibited-list; local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Letrozole is listed by name under Section S4.1 (Aromatase Inhibitors) as a Specified Substance alongside anastrozole, exemestane, aminoglutethimide, and other named AIs. Section S4 covers Hormone and Metabolic Modulators. The S4.1 catch-all language extends coverage to "and other compounds with similar chemical structure or similar biological effect(s)" — which would cover any future investigational AI compounds with comparable mechanism.
6. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; ncic ctg map.3 Study Investigators. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25):2381-91.(PMID 21639806 · NCT00083174)

• Testosterone — discussed together in this entry's stacks section
• Clomiphene / Enclomiphene — discussed together in this entry's stacks section
• Anastrozole — same mechanism class
• Exemestane — same mechanism class